Nymox's Alzheimer Urine Test Now Available As Kit in Europe

Nymox Pharmaceutical has announced there will be distribution agreements for the marketing and sale of its AlzheimAlert test kit with medical diagnostic companies in Europe. The AlzheimAlert device technology uses patient urine samples to measure levels of a biomarker for Alzheimer's disease, providing physicians with a valuable tool for the diagnosis of Alzheimer's disease. Nymox has announced the certification of its AlzheimAlert test kit with a CE Mark, making the device available for sale in the European Union.

Reuters (http://today.reuters.com/stocks/QuoteCompanyNewsArticle.aspx?view=PR&symbol=NYMX.O&storyID=155246%2B11-Feb-2005%2BBW)